Passage Bio to Report Fourth Quarter and Full-Year 2021 Financial Results on March 3, 2022

Rhea-AI Summary

Passage Bio (NASDAQ: PASG) announced a conference call on March 3, 2022, at 8:30 a.m. ET, to discuss its fourth quarter and full-year 2021 financial results and recent business highlights. The call can be accessed by dialing 833-528-0605 (domestic) or 830-221-9711 (international), using conference ID 4137048. A live audio webcast will also be available on Passage Bio's investor website. The company, focused on genetic therapies for CNS disorders, collaborates with the University of Pennsylvania to advance its gene therapy pipeline.

PHILADELPHIA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 3, 2022 to report its fourth quarter and full-year 2021 financial results and discuss recent business highlights.

To access the live conference call, please dial 833-528-0605 (domestic) or 830-221-9711 (international) and refer to conference ID 4137048. A live audio webcast of the event will be available on the Investors & News section of Passage Bio’s website at investors.passagebio.com. The archived webcast will be available on Passage Bio's website approximately two hours after the completion of the event and for 30 days following the call.

About Passage Bio

At Passage Bio (Nasdaq: PASG), we are on a mission to provide life-transforming genetic medicines for patients with CNS diseases that replace their suffering with boundless possibility, all while building lasting relationships with the communities we serve. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. This provides our team with enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies into clinical testing. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at www.passagebio.com.

For further information, please contact:

Passage Bio Investors:

Stuart Henderson
Passage Bio
267-866-0114
shenderson@passagebio.com

Passage Bio Media:

Gwen Fisher
Passage Bio
215-407-1548
gfisher@passagebio.com

FAQ

When is Passage Bio's Q4 2021 earnings call?

Passage Bio's Q4 2021 earnings call is scheduled for March 3, 2022, at 8:30 a.m. ET.

How can I access the Passage Bio earnings call?

You can access the earnings call by dialing 833-528-0605 (domestic) or 830-221-9711 (international) using conference ID 4137048, or by tuning into the live audio webcast on their investor website.

What is the focus of Passage Bio?

Passage Bio is focused on developing transformative genetic therapies for central nervous system disorders.

What partnership does Passage Bio have?

Passage Bio has a collaboration and licensing agreement with the University of Pennsylvania’s Gene Therapy Program to support their gene therapy development.